Compare · CLPT vs DXCM
CLPT vs DXCM
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 72.7x CLPT ($386.6M).
- Over the past year, CLPT is down 3.3% and DXCM is down 14.9% - CLPT leads by 11.6 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 18 for CLPT).
- DXCM has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- ClearPoint Neuro Inc.
- DexCom Inc.
- Price
- $12.88-10.28%
- $72.84+0.38%
- Market cap
- $386.6M
- $28.11B
- 1M return
- +12.20%
- +20.73%
- 1Y return
- -3.30%
- -14.94%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 18
- 26
- Recent ratings
- 5
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CLPT
- Director Richards Timothy T. sold $65,901 worth of shares (5,415 units at $12.17), decreasing direct ownership by 6% to 87,198 units (SEC Form 4)
- ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form 4 filed by Director Johnson B Kristine
- SEC Form 4 filed by Director Liau Linda M.
- SEC Form 4 filed by Director Fallon Lynnette C
- SEC Form 4 filed by Director Fletcher R John
- Director Klein Matthew B. sold $185,440 worth of shares (16,000 units at $11.59), decreasing direct ownership by 25% to 46,935 units (SEC Form 4)
- SEC Form 4 filed by Director Richards Timothy T.
- Director Fallon Lynnette C converted options into 12,417 shares and sold $56,714 worth of shares (5,091 units at $11.14) as part of a pre-agreed trading plan, increasing direct ownership by 18% to 48,227 units (SEC Form 4)
- Director Klein Matthew B. converted options into 12,417 shares, increasing direct ownership by 25% to 62,935 units (SEC Form 4)
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)